In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Redesign: FDA's Opening Statement to Stakeholders

This article was originally published in RPM Report

Executive Summary

Center for Drug Evaluation & Research Director Janet Woodcock kicked off FDA’s two day feedback meeting on the REMS July 27 with a construction analogy: FDA is still in the process of building a new house, but it is clear that there needs to be a redesign. Here are her opening remarks, from the official transcript of the meeting.
Advertisement

Related Content

The New Drug Safety Committee Members
REMS 2.0: FDA Refining New Drug Safety Tools

Topics

Advertisement
UsernamePublicRestriction

Register

PS080763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel